Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone: clinical development: north American results.

S R Marder1

  • 1West Los Angeles Veterans Affairs Medical Center, Brentwood Division, CA.

Clinical Neuropharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition.

Psychological medicine·2017
Same author

Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder.

Translational psychiatry·2017
Same author

Repurposing Drugs for Cognition in Schizophrenia.

Clinical pharmacology and therapeutics·2016
Same author

Efficient light emission from inorganic and organic semiconductor hybrid structures by energy-level tuning.

Nature communications·2015
Same author

Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.

European psychiatry : the journal of the Association of European Psychiatrists·2014
Same author

Adsorption studies of a phosphonic acid on ITO: film coverage, purity, and induced electronic structure changes.

Physical chemistry chemical physics : PCCP·2014
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Risperidone effectively treats schizophrenia symptoms at a 6 mg daily dose. This dosage outperformed haloperidol with fewer side effects, offering a promising treatment option.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Schizophrenia is a chronic mental disorder characterized by positive and negative symptoms.
  • Current treatments often have limitations regarding efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of risperidone in treating schizophrenia.
  • To determine the optimal effective dosage of risperidone.

Main Methods:

  • A multicenter clinical trial was conducted.
  • Patients with schizophrenia received varying doses of risperidone and haloperidol.

Main Results:

  • Risperidone demonstrated significant efficacy in treating both positive and negative symptoms of schizophrenia.
  • A daily dose of approximately 6 mg of risperidone was found to be the most effective.

Related Experiment Videos

  • This optimal dose of risperidone was superior to 20 mg of haloperidol and was associated with a low incidence of extrapyramidal side effects.

    • Conclusions:

    • Risperidone is an effective antipsychotic medication for schizophrenia.
    • The 6 mg daily dose represents an optimal balance of efficacy and tolerability.
    • Risperidone offers an improved side effect profile compared to haloperidol for schizophrenia management.